Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions
- PMID: 20856693
- PMCID: PMC2941213
- DOI: 10.2217/fnl.10.31
Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions
Abstract
With Alzheimer's disease increasing in prevalence and public awareness, more people are becoming interested in learning their chances of developing this condition. Disclosing Alzheimer's disease risk has been discouraged because of the limited predictive value of available tests, lack of prevention and treatment options, and concerns regarding potential psychological and social harms. However, challenges to this status quo include the availability of direct-to-consumer health risk information (e.g., genetic susceptibility tests), as well as a growing literature suggesting that people seeking risk information for Alzheimer's disease through formal education and counseling protocols generally find it useful and do not experience adverse effects. This paper reviews current and potential methods of risk assessment for Alzheimer's disease, discusses the process and impact of disclosing risk to interested patients and consumers, and considers the practical and ethical challenges in this emerging area. Anticipated future directions are addressed.
Conflict of interest statement
This work was supported by grants from the NIH (HG02213) and the Alzheimer’s Association (IIRG-07–58189). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
The authors thank Lindsay Zausmer for her assistance with manuscript preparation.
References
Bibliography
-
- Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–191. - PubMed
-
-
Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2009;5(3):234–270.. ▪▪ A public health review of epidemiologic statistics, disease impact on caregiving and healthcare costs, and advances in risk factor knowledge, diagnosis and treatment for Alzheimer’s disease (AD) and mild cognitive impairment.
-
-
- Neumann PJ, Hammitt JK, Mueller C, et al. Public attitudes about genetic testing for Alzheimer’s disease. Health Aff. (Millwood) 2001;20(5):252–264. - PubMed
-
- Morris JC. Dementia Update 2005. Alzheimer Dis. Assoc. Disord. 2005;19(2):100–117. - PubMed
-
- Offit K. Genomic profiles for disease risk: predictive or premature? JAMA. 2008;299(11):1353–1355. - PubMed
Websites
-
- Alzheimer’s Association. Maintain your brain. www.alz.org/we_can_help_brain_health_maintain_your_brain.asp.
-
- Siteman Cancer Center. Your disease risk. 2007. www.yourdiseaserisk.wustl.edu.
-
- National Cancer Institute. Breast Cancer Risk Assessment Tool. www.cancer.gov/bcrisktool.
-
- Sipkoff M. Alzheimer’s drug pipeline is robust, and usage is quickly expanding. Managed Care Magazine. 2009. www.managedcaremag.com/archives/0906/0906.alzheimers.html. - PubMed
-
- Direct-to-consumer genetic testing companies: Genetics and Public Policy Center. 2009. www.dnapolicy.org/resources/DTCcompanieslist.pdf.
Patent
-
- US5508167. 1996.
Grants and funding
LinkOut - more resources
Full Text Sources